Phytochemical and Computational Discovery of Potent Xanthine Oxidase Inhibitors From Ziziphus lotus L. Leaves and Seeds
Chemistry & Biodiversity · 2026
DOI: 10.1002/cbdv.202502169 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2026. Verfasst von Fatna Bellahcene und 8 weiteren Autor:innen. Beteiligte Einrichtung: Fundamental Sciences Laboratory, Faculty of Sciences, Amar Telidji University, Laghouat, Algeria. Hauptthemen laut MEDLINE: Xanthine Oxidase, Enzyme Inhibitors, Phytochemicals, Seeds. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Ziziphus lotus (L.), traditionally recognised for its anti‐inflammatory and antioxidant properties, has received limited scientific exploration regarding its potential as an antigout agent. This study provides the first investigation of the inhibitory capacity of Z. lotus seed and leaf extracts against bovine xanthine oxidase (BXO), a key enzyme in uric acid biosynthesis and the pathogenesis of gout. To characterise its bioactive constituents, the potent extract was subjected to liquid chromatography–high‐resolution electrospray ionisation mass spectrometry (LC–HRESIMS)‐based phytochemical profiling. In vitro evaluation confirmed potent inhibitory effects, with the seed extract (IC 50 = 40.63 ± 0.41 µg/mL) showing superior activity over the leaf extract (IC 50 = 61.06 ± 1.15 µg/mL). LC–HRESIMS profiling of the seed extract identified fourteen metabolites, dominated by syringic acid (16 240.00 µg/g extract), sinapinic acid (3688.80 µg/g extract), and rutin (1918.00 µg/g extract) as the major constituents. A computational study focused on phytochemicals not previously assessed against XO; molecular docking demonstrated strong binding interactions to the target protein, suggesting promising inhibitory potential. ADMET and drug‐likeness assessments highlighted (+)‐ trans taxifolin as the most promising candidate for drug development. Overall, these findings establish Z. lotus seeds as a valuable source of natural xanthine oxidase inhibitors and underscore their potential as novel phytotherapeutic agents for treating gout and hyperuricemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fundamental Sciences Laboratory, Faculty of Sciences, Amar Telidji University, Laghouat, Algeria.
- Laboratory of Applied Sciences and Didactic, Higher Normal School of Laghouat, Laghouat, Algeria.
- Department of Analytical Chemistry, Faculty of Pharmacy, Bezmialem Vakif University, İstanbul, Türkiye.
- Department of Pharmacognosy, Faculty of Pharmacy, Bezmiâlem Vakıf University, İstanbul, Türkiye.
- Drug Application and Research Center (DARC), Bezmiâlem Vakif University, İstanbul, Türkiye.
- Department of Dental Medicine, University of Ghardaia, Ghardaia, Algeria.
ORCID-Profile: Fatna Bellahcene, Khedidja Benarous, Ebru Erol, Talia Serseg, Gülaçtı Topçu, Abderahmane Linani, Hicham Bouakkaz, Alaeddine Kaouka, Mohamed Yousfi
Zitieren
APA
Bellahcene, F., Benarous, K., Erol, E., Serseg, T., Topçu, G., Linani, A., Bouakkaz, H., Kaouka, A., & Yousfi, M. (2026). Phytochemical and Computational Discovery of Potent Xanthine Oxidase Inhibitors From Ziziphus lotus L. Leaves and Seeds. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202502169
Vancouver
Bellahcene F, Benarous K, Erol E, Serseg T, Topçu G, Linani A, et al. Phytochemical and Computational Discovery of Potent Xanthine Oxidase Inhibitors From Ziziphus lotus L. Leaves and Seeds. Chemistry & Biodiversity. 2026. doi:10.1002/cbdv.202502169
BibTeX
@article{Bellahcene2026,
author = {Bellahcene, Fatna and Benarous, Khedidja and Erol, Ebru and Serseg, Talia and Topçu, Gülaçtı and Linani, Abderahmane and Bouakkaz, Hicham and Kaouka, Alaeddine and Yousfi, Mohamed},
title = {Phytochemical and Computational Discovery of Potent Xanthine Oxidase Inhibitors From Ziziphus lotus L. Leaves and Seeds},
journal = {Chemistry & Biodiversity},
year = {2026},
doi = {10.1002/cbdv.202502169}
}
EUVIMED